French Pharma Industry Pays The Price For Country’s Financial Woes
This article was originally published in The Pink Sheet Daily
Executive Summary
In an effort to shore up its credit rating, the French government has turned the financial screw on pharmaceutical manufacturers.
You may also be interested in...
The Year Ahead In Europe: More Price Cuts, More Austerity
Further austerity plans will be drawn up and drug price cuts implemented in Europe during 2012, as governments try to come to grips with their debts and with the eurozone currency crisis.
Rx Class Action Suits May Come To France In Response To Mediator Scandal
French Senate offers a class action mechanism that could impose a 50% penalty on drug firms.
Mediator Scandal Provokes Flurry of French Health Reforms But Impact Is Hard To Gauge Until The Dust Settles
France is facing various reforms to its health care system as a direct result of the scandal involving Servier’s diabetes drug Mediator (benfluorex), which may have caused up to 500 deaths.